A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

IGC Pharma, Inc. ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease has been officially named CALMA (Calming Agitation in Alzheimer's).

Cambridge Cognition announced the use of its ‘CANTAB’ cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for ‘Cobenfy’, a newly FDA-approved treatment ...

Imagine having a digital carbon copy of yourself that physicians could use to predict long-term risks for disease, assess how your body may respond to treatment, and simulate surgeries in advance. A ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set ...

Turnstone Biologics Corp. (NASDAQ:TSBX – Get Free Report) was down 9.1% on Wednesday . The stock traded as low as $0.48 and last traded at $0.51. Approximately 121,559 shares changed hands during ...

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or ...

The results build on two harmonized Phase I clinical trials, focusing on ... Aug. 28, 2024 — More than two decades ago, a research team discovered a type of T cell in humans that suppresses the ...

It’s more important to practice regularly than to sporadically do longer sessions. 20 minutes a day is a better bet than 60 ...

The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.

Explore how inhibiting myostatin can promote muscle mass in men, addressing sarcopenia, GLP-1 medication effects, and aging ...